
Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure includes patients with and without type 2 diabetes, although the topline results did not specify if results were similar in these 2 populations.
Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure includes patients with and without type 2 diabetes, although the topline results did not specify if results were similar in these 2 populations.
The neighborhood you live in not only impacts your health but also can predict if you’ll die prematurely, according to new research published in the journal Health & Place.
Antenatal exposure to higher levels of fluoride was correlated to lower IQ scores in children aged 3 to 4 years, hinting at a possible need for fluoride intake reduction during pregnancy.
Researchers recommended strategies for providers to think about when managing this population.
Planned Parenthood decides to withdraw from the Title X program after bid to halt Trump administration plan is rejected by courts; measles outbreaks are increasing, threatening to remove elimination status in the United States; a study finds that premature babies are not receiving necessary vaccinations.
During the menopause transition, women with type 2 diabetes are more likely to have sleep disturbances due to an alteration in their hormonal response to insulin.
Biologics have become the standard of care for rheumatoid arthritis (RA) that fails to respond adequately to conventional disease-modifying antirheumatic agents (DMARDs), and overall, these agents are safe and effective. However, an association between treatment with anti–tumor necrosis factor (anti-TNF) agents and new-onset psoriasis in patients with RA has been observed.
Study authors suggested that future research involve developing and testing strategies for business investment in building healthier communities.
A new study said antimicrobial resistance rates may display seasonal variation, peaking in winter, that could result from the seasonality of infectious diseases and accompanied antibiotic use.
Planned Parenthood's efforts to halt the Trump administraion's "gag rule" have been denied by a federal appeals court; e-cigarette usage is being probed by the CDC for links to reported cases of lung illnesses; public health experts warn that Trump's new administration plan will lead to ailing immigrants.
Prior to the launch of solriamfetol (Sunosi) for narcolepsy and obstructive sleep apnea, the Drug Enforcement Administration designated it as a Schedule IV drug, indicating that it has a low potential for abuse and a low risk of dependence. Around the same time, results from the phase 3 TONES 3 study were published, showing the drug’s efficacy in increasing wakefulness and reducing sleepiness.
Interest in omega-3 fatty acids have increased since publication of the results of REDUCE-IT.
Researchers found underlying associations of insomnia with heart disease and stroke.
Despite advances in therapies for diabetes, those living with the disease are not faring better in reaching treatment targets due to lack of access to care, starting with the ability to be properly diagnosed.
While pulmonary rehabilitation (PR) is an evidence-based and cost-effective treatment for people with chronic obstructive pulmonary disease (COPD), uptake of and compliance with this intervention has been poor. For patients who decline PR, inspiratory muscle training (IMT), which involves strengthening the inspiratory muscles by increasing their workload, may be an option, particularly as it can be performed in the home instead of in a clinic.
Blood clots, or venous thromboembolism, remains a leading causes of death and healthcare spending in patients with cancer.
Researchers said taking genetic variability into account in the future will be helpful not only to understand the course of Parkinson disease but also to minimize heterogeneity in clinical trials.
The panel voted against recommending the prevention pill for use in cisgender women due to inadequate data on efficacy in this patient population.
A psoriasis researcher discusses a new class of psoriasis treatments.
Health plans on the Affordable Care Act (ACA) exchanges will be required to display quality ratings starting with the 2020 plan year, according to an announcement from CMS, which is expanding the 5-star rating system it uses on Medicare plans to the health insurance exchanges.
This week, the top managed care stories included the Trump administration looking to bar legal immigrants from using public benefits; a study in The American Journal of Managed Care® finding that a law to limit surprise medical bills is working; data on Affordable Care Act enrollment showing the effect of subsidies.
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
The researchers called for more work to discover specific exposures in patients with leukemia that lead to infections after treatment ends.
The August issue of The American Journal of Managed Care® (AJMC®) featured research on surprise medical billing policies, social determinants of health, and the value of chimeric antigen receptor T-cell therapies, among other topics. Here are 5 findings from research published in the issue.
Parents treated for tobacco addiction within a pediatric office were associated with a significant decline in smoking rates as opposed to standard offices.
Generic drug makers are being accused of blocking a Congressional probe into their pricing practices; Illinois has become the first state to require insurance companies to pay for EpiPens for kids in cases of severe allergic reactions; Tufts Health Plan and Harvard Pilgrim Health will merge to create a new company covering 2.4 million people across New England.
The authors call for more personalized screening protocols to find cancer earlier in younger adults, as well as public health efforts to address obesity.
FDA's approval of entrectinib for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors represents a new paradigm in cancer treatment; It treats a cancer based on a common biomarker seen across different tumors rather than based on the location in the body where the cancer originated. The FDA also gave approval to entrectinib for the treatment of adults with metastatic non–small cell lung cancer whose tumors are ROS1 positive.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.